Party members of pharmaceutical companies learn the spirit of "7.26" speech
Release time:
2020-08-14
Party Members of Pharmaceutical Company Learn the Spirit of "7.26 " Speech
News from our newspaper 10# September 16 , the General Party Branch of Jinhua Pharmaceutical Company held an enlarged general branch meeting to earnestly study the important speech made by General Secretary Xi Jinping 7 March 26 at the special seminar for major provincial and ministerial leaders. Members of the general party branch, members of the administrative team, and all members of each branch all participated. The
meeting was presided over by Yuan Jie, secretary of the general branch. He said that when the party's 19th congress was held, the organization and study of the general secretary's "7.26 " speech should be guided by the spirit of the "7.26 " speech and do a solid job in welcoming the party's 19th congress propaganda work. To study the "7.26 " speech, it is important to grasp the key words of the speech, deeply understand the rich connotation and spiritual essence of the speech, firmly grasp that socialism with Chinese characteristics is the theme of all the theories and practices of the party since the reform and opening up, hold high the great banner of socialism with Chinese characteristics, and firmly establish the "four self-confidence" of socialism with Chinese characteristics; We must learn to analyze and judge the current world conditions, national conditions, we should see the achievements and opportunities, but also see the shortcomings and shortcomings, enhance the sense of hardship, and be prepared for danger in times of peace; fully understand the theory pointed out by General Secretary Xi that the comprehensive and strict governance of the party is always on the road, strengthen the study of theoretical knowledge, and make ideals and beliefs more firm; earnestly study and understand, and earnestly unify thoughts and actions into the spirit of the speech, so as to guide and promote all kinds of work. Wu Weisheng, general manager of
, said that to learn the speech spirit of "7.26 ", it is important to integrate theory with practice and practice the speech spirit with practical actions. Since the beginning of this year, the pharmaceutical industry has faced policy adjustments and changes such as the lowest price linkage, second bargaining, and the two-vote system. It is necessary to see the risks brought about by policy changes, see its own shortcomings and shortcomings, and regard it as an opportunity and challenge. He called on all party members, especially party members and cadres, to play an exemplary and leading role in their work, enhance their awareness of hardship, lead all staff to use their brains, think of countermeasures, redouble their efforts, meet challenges, and shoulder their due responsibilities in their respective posts. At the meeting of
, all Party members also studied the documents of the Party committee of the group company, and put forward opinions and suggestions on the leading group and members of the group company on the aspects of political qualification, discipline implementation qualification, moral character qualification and role playing qualification.
The general party branch of the pharmaceutical company requires each party branch to hold a general meeting of all party members of the branch after the meeting, focus on studying and implementing General Secretary Xi's "Speech 7.26 " and the spirit of the 19th congress, and put forward suggestions in connection with the actual situation of the enterprise. (Fan Tufa)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page